Bristol-Myers Squibb has taken ownership of Celgene's drug.
2 reports, 2 independent
Updated Aug 18
Gone quiet
- Reports
- 2
- Developments
- 2
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Bristol-Myers Squibb has taken ownership of Celgene's drug.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.The BMS/Celgene acquisition is facing legal challenges regarding contingent payments and market competition.1 source
Bristol-Myers Squibb now owns Celgene's drug.1 source
Keep exploring
The entities involved
-
Bristol-Myers Squibb
American pharmaceutical company
-
Celgene
American biopharmaceutical company
Nothing else this week.
Related events
- Cocrystal Pharma and Bristol-Myers Squibb are competing for investment as healthcare companies.
- Bristol-Myers Squibb and Pfizer are co-marketing Eliquis, while both companies are noted as dividend payers.
- Bristol-Myers Squibb and Johnson & Johnson are both companies that are currently targets of LB Pharmaceuticals.
- Manufacturers Life Insurance Company reduced its share position in Bristol-Myers Squibb.
- Pfizer is based in New York and Bristol-Myers Squibb is based in Princeton, New Jersey.
Coverage
Newest first; wire copies grouped- biopharmadive.com
- ACCESS NewswireActuate Therapeutics Advances a New Era in Oncology with Potential Universal Backbone Therapy Phase 2 study showed a doubling of the survival rate of metastatic pancreatic cancer patients at Year 1,